Reference Source

ALMENAT SAS

For ALMENAT SAS, import alert is 54-16; import alert name is "DETENTION WITHOUT PHYSICAL EXAMINATION OF PRODUCTS THAT ARE MARKETED AS FOODS, INCLUDING PRODUCTS MARKETED AS DIETARY SUPPLEMENTS, THAT CONTAIN AN ACTIVE PHARMACEUTICAL INGREDIENT"; country is COLOMBIA; address is Av 39 Oeste No 10 Oeste , Cali, COLOMBIA; date published is 07/09/2026, verified against its source on 2026-08-06.

Firm
ALMENAT SAS verified
Import alert
54-16 verified
Import alert name
"DETENTION WITHOUT PHYSICAL EXAMINATION OF PRODUCTS THAT ARE MARKETED AS FOODS, INCLUDING PRODUCTS MARKETED AS DIETARY SUPPLEMENTS, THAT CONTAIN AN ACTIVE PHARMACEUTICAL INGREDIENT" verified
Country
COLOMBIA verified
Address
Av 39 Oeste No 10 Oeste , Cali, COLOMBIA verified
Date published
07/09/2026 verified
Product code
54 - - - -- Vitamins/Minerals (Human/Animal); Proteins/Unconv Dietary Supp (Human) | 65 P - - 02 Sildenafil Citrate (Regulator) | 66 V - - 99 Miscellaneous Patent Medicines, Etc. verified
Product
biQ-FEL | biQ-FEL | biQ-FEL verified
FDA notes
FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. | FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. | FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. verified
Sourceaccessdata.fda.gov
Verified2026-08-06
Review by2026-10-05
DatasetFDA import alert red lists: firms subject to detention without physical examination

What the source says

ALMENAT SAS Date Published : 07/09/2026 Av 39 Oeste No 10 Oeste , Cali, COLOMBIA 54 - - - -- Vitamins/Minerals (Human/Animal); Proteins/Unconv Dietary Supp (Human) Date Published: 07/09/2026 Desc: biQ-FEL Notes: FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. 65 P - - 02 Sildenafil Citrate (Regulator) Date Published: 07/09/2026 Desc: biQ-FEL Notes: FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 07/09/2026 Desc: biQ-FEL Notes: FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil.

accessdata.fda.gov, retrieved 2026-08-06

Source

Last verified against source: 2026-08-06. Due for re-check by 2026-10-05. This page as Markdown · OKF bundle · full dataset as JSON.